Activation of natural killer cells by bacillus Calmette-Guérin

European Urology

Volumn 39, Issue 5, 2001, Pages 518-524

  Brandau, Sven ^a,b   Böhle, Andreas ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Bacillus Calmette Gu rin; Bladder tumor; Immunotherapy; Natural killer cells

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER TUMOR; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; NATURAL KILLER CELL; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BCG VACCINE; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; URINARY BLADDER NEOPLASMS;

EID: 0034912476     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052497     Document Type: Article

References (28)

1. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors
2. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder
3. Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study
4. 5-Year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma
5. BCG immunotherapy of bladder cancer: 20 Years on
6. Requirement of a thymus-dependent immune response for BCG-mediated antitumor activity
7. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer
8. Presence of activated lymphocytes in the urine of patients after intravesical immunotherapy with bacillus Calmette-Guérin
9. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer
10. Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy
11. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guérin
12. Intravesical Evans strain BCG therapy. Quantitative immunohistochemical analysis of the immune response within the bladder wall
13. Induction of bacillus Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro
14. The induction of bacillus Calmette-Guérin-activated killer cells requires the presence of monocytes/macrophages and T-helper type 1 cells
15. Cytotoxicity of bacillus Calmette-Guérin-activated killer cells towards bladder cells is specific for urothelial cells of cancerous origin
16. Optimizing syngeneic orthotopic murine bladder cancer (MB49)
17. Human natural killer cells
18. Intravesical and systemic chemotherapy of murine bladder cancer
19. The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function
20. Non-major histocompatibility complex-restricted cytotoxic activity of blood mononuclear cells stimulated with secreted mycobacterial proteins and other mycobacterial antigens
21. Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein
22. Contribution of membrane-associated cytotoxic proteins to cytolysis of L929 and K562 target cells mediated by LAK cells with different phenotypes
23. Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells
24. Natural killer cells and tumor therapy
25. The role of natural killer cells in immune surveillance of cancer
26. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells
27. CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin-2 and the c-kit ligand
28. NK cells and apoptosis